Document -
Olink Proteomics AB announce strategic acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays
Olink today announced the acquisition of Agrisera, a Swedish company specializing in polyclonal and monoclonal antibody production. The acquisition is an important milestone for Olink in its aim to rapidly increase the number of assays available for its unique PEA technology which allows for an unparalleled multiplexing with rigorous validation for each assay.
-
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
- File format: .pdf
